Commercially Purchased Bebtelovimab Reimbursement (IB 22-28)

Date: 09/08/22

Louisiana Healthcare Connections would like to share with providers that the commercial distribution of the COVID-19 treatment medication Bebtelovimab (Q0222) began on August 15, 2022. This is in addition to stock of this medication providers may have that was supplied by the federal government at no cost.

Effective for dates of service on or after August 15, 2022, Louisiana Medicaid will require modifier “UC” to identify that the COVID-19 medication administered was commercially purchased. Providers are to use the same administration codes for both the purchased product and the medication supplied by the federal government.

There are no changes for submitting claims related to the government-supplied medication. If the federal government provided the medication, then no modifier is to be appended and reimbursement is $0. Seeking reimbursement for the government-provided medication is subject to review, recoupment and further sanctions

The COVID-19 Vaccine and Treatment fee schedule has been revised to reflect this update. The fee schedule is available on the Medicaid website.

As Louisiana Healthcare Connections updates our systems, we will recycle any impacted claims within 15 days of our system revision with no action needed by the provider. 

For questions related to this information as it pertains to Fee-for-Service Medicaid claims processing, providers can contact Gainwell Technologies Provider Services at (800) 473-2783 or (225) 924-5040. Or contact your dedicated provider network specialist at 1-868-595-8133.